| Ayuda Home Health Care Services Llc 1515 Cessna Suite 201, El Paso, TX, 79925 | |
| (915) 231-9494 |
News Archive
Some big name health facilities sometimes draw entire physician or research groups from other institutions.
New research has shown that a protein, known as IL-13, could be the key to the development of fibrosis in Crohn's disease. This breakthrough could help to advance new medicines to treat people suffering with the disease.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Glycosylated IL-7, Preparation and Uses", US Patent Application Number 11/996,176. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued.
Diabetes and dementia are rising dramatically in the United States and worldwide. In the last few years, epidemiological data has accrued showing that older people with diabetes are significantly more likely to develop cognitive deterioration and increased susceptibility to onset of dementia related to Alzheimer's disease.
› Verified 8 days ago
| Name | Ayuda Home Health Care Services Llc |
|---|---|
| Location | 1515 Cessna Suite 201, El Paso, Texas |
| Hospice ID | 741584 |
| Category | Freestanding Hospice |
| Ownership Type | Proprietary - Other |
| Profit Type | FOR PROFIT |
| Accreditation Provider | Community Health Accreditation Partner (CHAP) |
| SSA county code | 480 |
News Archive
Some big name health facilities sometimes draw entire physician or research groups from other institutions.
New research has shown that a protein, known as IL-13, could be the key to the development of fibrosis in Crohn's disease. This breakthrough could help to advance new medicines to treat people suffering with the disease.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Glycosylated IL-7, Preparation and Uses", US Patent Application Number 11/996,176. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued.
Diabetes and dementia are rising dramatically in the United States and worldwide. In the last few years, epidemiological data has accrued showing that older people with diabetes are significantly more likely to develop cognitive deterioration and increased susceptibility to onset of dementia related to Alzheimer's disease.
› Verified 8 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | Not Available | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | Not Available | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | Not Available | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | Not Available | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | Not Available | 97.3 |
| Patients who got timely treatment for shortness of breath | Not Available | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | Not Available | 93.3 |
News Archive
Some big name health facilities sometimes draw entire physician or research groups from other institutions.
New research has shown that a protein, known as IL-13, could be the key to the development of fibrosis in Crohn's disease. This breakthrough could help to advance new medicines to treat people suffering with the disease.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Glycosylated IL-7, Preparation and Uses", US Patent Application Number 11/996,176. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued.
Diabetes and dementia are rising dramatically in the United States and worldwide. In the last few years, epidemiological data has accrued showing that older people with diabetes are significantly more likely to develop cognitive deterioration and increased susceptibility to onset of dementia related to Alzheimer's disease.
› Verified 8 days ago
| Home Health Aides | 0.3 |
| Counselors | 0.2 |
| Licensed Practical or Vocational Nurses | 0.5 |
| Medical Social Workers | 0.2 |
| Registered Nurses | 0.75 |
| Other Personnel | 0.85 |
| Total Employees | 2.8 |
|---|
News Archive
Some big name health facilities sometimes draw entire physician or research groups from other institutions.
New research has shown that a protein, known as IL-13, could be the key to the development of fibrosis in Crohn's disease. This breakthrough could help to advance new medicines to treat people suffering with the disease.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Glycosylated IL-7, Preparation and Uses", US Patent Application Number 11/996,176. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued.
Diabetes and dementia are rising dramatically in the United States and worldwide. In the last few years, epidemiological data has accrued showing that older people with diabetes are significantly more likely to develop cognitive deterioration and increased susceptibility to onset of dementia related to Alzheimer's disease.
› Verified 8 days ago
| Others | 1 |
| Total Volunteers | 1 |
|---|
News Archive
Some big name health facilities sometimes draw entire physician or research groups from other institutions.
New research has shown that a protein, known as IL-13, could be the key to the development of fibrosis in Crohn's disease. This breakthrough could help to advance new medicines to treat people suffering with the disease.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Glycosylated IL-7, Preparation and Uses", US Patent Application Number 11/996,176. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued.
Diabetes and dementia are rising dramatically in the United States and worldwide. In the last few years, epidemiological data has accrued showing that older people with diabetes are significantly more likely to develop cognitive deterioration and increased susceptibility to onset of dementia related to Alzheimer's disease.
› Verified 8 days ago
| Hospice Of El Paso Inc Location: 1440 Miracle Way, El Paso, Texas, 79925 Phone: (915) 231-9494 |
| La Mariposa Hospice Location: 1250 East Cliff Suite 5-e, El Paso, Texas, 79902 Phone: (915) 231-9494 |
| Gentiva Hospice Location: 7500 Viscount Suite C83, El Paso, Texas, 79925 Phone: (915) 231-9494 |
| Envision Hospice Location: 8929 Viscount Upper Level, El Paso, Texas, 79925 Phone: (915) 231-9494 |